On November 10, DUALITYBIO-B rose 5.18% in regular trading, with shares at HK$109.5 and turnover of HK$10.52 million.
The clearest recent catalyst was continued insider accumulation and company buybacks. Recent market updates showed chairman Zhu Zhongyuan bought 30,000 shares on November 6 at an average price of HK$104.765, involving about HK$3.14 million, lifting his long position to about 16.2297 million shares and his stake to 17.65%.
This followed a string of market purchases in the preceding sessions: 30,000 shares on November 5, 30,000 on November 4, 30,000 on November 3, and 30,000 on November 2, after an earlier 10,000-share purchase on October 30. Separately, the company had also been conducting buybacks, alongside a previously announced voluntary lock-up by directors and senior management, reinforcing signals of management confidence after late-October clinical-trial-related volatility.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments